Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines

The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT, is an attractive therapeutic target in breast cancer. Everolimus, an allosteric mTOR inhibitor that inhibits the mTOR functional complex mTORC1, is approved for treatment of estrogen receptor positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Euphemia Y., Askarian-Amiri, Marjan, Finlay, Graeme J., Rewcastle, Gordon W., Baguley, Bruce C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492962/
https://www.ncbi.nlm.nih.gov/pubmed/26148118
http://dx.doi.org/10.1371/journal.pone.0131400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492962/
https://www.ncbi.nlm.nih.gov/pubmed/26148118
http://dx.doi.org/10.1371/journal.pone.0131400

Ejemplares similares